Literature DB >> 24662736

An epigenetic screen unmasks metallothioneins as putative contributors to renal cell carcinogenesis.

Imad Alkamal1, Odiljon Ikromov, Angelika Tölle, Tom Florian Fuller, Ahmed Magheli, Kurt Miller, Hans Krause, Carsten Kempkensteffen.   

Abstract

OBJECTIVE: Functional epigenetic studies aimed to re-express transcriptionally silenced genes in renal cell carcinoma (RCC) may facilitate the ongoing search for appropriate markers supporting clinical decision-making.
METHODS: The RCC cell line A-498 was treated with the DNA methyltransferase inhibitor zebularine under low-cytotoxicity conditions. RNA chip analyses revealed several upregulated transcripts that were further validated by qPCR on 49 matched pairs of human kidney tissues to identify suitable marker candidates.
RESULTS: Members of the metallothionein (MT) group were remarkably downregulated in tumor tissues. MT1G and MT1H expression was decreased in 98% of cases, whereas MT2A expression was downregulated in 73% of all cases. Comparison of 308 reactivated transcripts upregulated more than 1.5-fold to published data revealed a high number of shared candidates, which supports the consistency of this experimental approach.
CONCLUSION: MTs were found to be transcriptionally inactivated in human RCC. Our observations support the hypothesis of a possible involvement of these metalloproteins in renal cell carcinogenesis. Additional functional studies of these genes may provide clues for understanding renal cancers as essentially metabolic diseases.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24662736     DOI: 10.1159/000357282

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

1.  Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.

Authors:  Michal Chovanec; Fadi Taza; Maitri Kalra; Noah Hahn; Kenneth P Nephew; Michael J Spinella; Costantine Albany
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

Review 2.  Targeting DNA Methyltranferases in Urological Tumors.

Authors:  Ângela Marques-Magalhães; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Front Pharmacol       Date:  2018-04-13       Impact factor: 5.810

Review 3.  The roles of metallothioneins in carcinogenesis.

Authors:  Manfei Si; Jinghe Lang
Journal:  J Hematol Oncol       Date:  2018-08-23       Impact factor: 17.388

4.  Evaluation of MT Family Isoforms as Potential Biomarker for Predicting Progression and Prognosis in Gastric Cancer.

Authors:  Mingfu Tong; Wenquan Lu; Hao Liu; Jian Wu; Mingzuo Jiang; Xin Wang; Jianyu Hao; Daiming Fan
Journal:  Biomed Res Int       Date:  2019-07-17       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.